Antibody Therapy for the Control of Viral Diseases: An Update

Author(s): Miriam Dibo, Eduardo C. Battocchio, Lucas M. dos Santos Souza, Matheus D. Veloso da Silva, Bruna K. Banin-Hirata, Milena M.M. Sapla, Poliana Marinello, Sérgio P.D. Rocha, Lígia C. Faccin-Galhardi*.

Journal Name: Current Pharmaceutical Biotechnology

Volume 20 , Issue 13 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


The epidemiological impact of viral diseases, combined with the emergence and reemergence of some viruses, and the difficulties in identifying effective therapies, have encouraged several studies to develop new therapeutic strategies for viral infections. In this context, the use of immunotherapy for the treatment of viral diseases is increasing. One of the strategies of immunotherapy is the use of antibodies, particularly the monoclonal antibodies (mAbs) and multi-specific antibodies, which bind directly to the viral antigen and bring about activation of the immune system. With current advancements in science and technology, several such antibodies are being tested, and some are already approved and are undergoing clinical trials. The present work aims to review the status of mAb development for the treatment of viral diseases.

Keywords: Immunotherapy, monoclonal antibodies, viral diseases, treatment, emerging viruses, immunotherapeutics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [1108 - 1121]
Pages: 14
DOI: 10.2174/1389201020666190809112704
Price: $58

Article Metrics

PDF: 13